FDA approves Teva leukemia drug - Israel Business, Ynetnews

   Israel News

Israel News
World News
Israel Opinion
Israel Business
Israel Culture
Israel Travel
New Treatment

Teva factory in Jerusalem (archives) Photo: Reuters
Teva factory in Jerusalem (archives) Photo: Reuters

FDA approves Teva leukemia drug

Israel-based generic drug maker gets approval for treatment for type of blood, bone marrow cancer called CML

Published: 10.28.12, 07:22 / Israel Business

The US Food and Drug Administration on Friday said it has approved a new leukemia treatment from Teva Pharmaceutical Industries Ltd. to be sold under the brand name Synribo.


The drug, also known as omacetaxine mepesuccinate, is approved to treat a type of the blood and bone marrow cancer called chronic myelogenous leukemia, or CML, in patients whose cancer has progressed after treatment with at least two drugs from a class called tyrosine kinase inhibitors.


Purchase Completed
Teva acquires rights to Huntexil for $26M / Associated Press
Israel-based drug company says acquisition includes all rights, assets and obligations relating to medication for treatment of Huntington disease
Full story

"Today's approval provides a new treatment option for patients who are resistant to or cannot tolerate other FDA-approved drugs for chronic or accelerated phases of CML," Richard Pazdur, director of the Office of Hematology and Oncology Products in FDA's Center for Drug Evaluation and Research, said in a statement.


Synribo, which is injected under the skin twice daily for 14 consecutive days over a 28-day cycle until white blood cell counts normalize, works by blocking proteins that help the development of cancerous cells.


It is the second CML drug approved by the FDA in recent weeks after the September approval of Pfizer Inc's Bosulif.


An estimated 5,430 Americans will be diagnosed with CML in 2012, according to the National Institutes of Health.


Synribo received an accelerated approval based on the disease response to the drug in studies. However it has yet to demonstrate an improvement in disease symptoms or an increased survival benefit in a clinical trial, the FDA and company said.


Israel-based Teva, the world's largest generic drug maker, has advanced its focus on developing new medicines, in part through its acquisition of the US biotech Cephalon.



commentcomment   PrintPrint  Send to friendSend to friend   
Tag with Del.icio.us Bookmark to del.icio.us


RSS RSS | About | Contact Us | Privacy Policy | Terms of use | Advertise with us | Site Map

Site developed by  YIT Advanced Technology Solutions